Lidokain Aguettant

Lidocaine, the active ingredient in Lidokain Aguettant, is a local anesthetic presented as a sterile injectable solution for infiltration, intradermal and intravenous use. It provides reversible loss of sensation for minor surgical and diagnostic procedures in adult and pediatric patients. GNH USA supplies Lidokain Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidokain Aguettant is a local anesthetic used to achieve temporary loss of sensation in targeted tissues. - Infiltration anesthesia: provides localized numbness for minor surgical procedures. - Intradermal anesthesia: enables precise skin anesthesia for diagnostic or cosmetic interventions. - Intravenous regional anesthesia: facilitates a Bier block for limb surgeries by producing reversible nerve blockade.

Lidokain Aguettant may cause adverse reactions at the injection site or systemically.

Common Side Effects: - Burning or stinging sensation at the injection site. - Tingling or numbness extending beyond the intended area. - Mild swelling or erythema around the injection site. - Transient dizziness or light‑headedness. - Nausea or mild headache.

Serious or Rare Side Effects: - Systemic toxicity presenting as seizures, confusion, or loss of consciousness. - Cardiovascular effects such as arrhythmias, hypotension, or cardiac arrest. - Allergic reactions ranging from urticaria to anaphylaxis. - Methemoglobinemia, a rare disorder affecting oxygen transport. - Persistent numbness or motor weakness beyond the expected duration.

When using Lidokain Aguettant, clinicians should observe several safety measures. - Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics. - Dosage calculation: base the dose on patient weight, procedure type, and route of administration. - Cardiovascular monitoring: observe for signs of toxicity, especially during intravenous use. - Hepatic function: use with caution in patients with impaired liver metabolism. - Pregnancy and lactation: assess risk‑benefit ratio before administration. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Lidokain Aguettant can interact with other medications, requiring careful management.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): increase risk of cardiotoxicity. - Beta‑blockers (e.g., propranolol): may potentiate cardiac depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise systemic lidocaine concentrations.

Moderate Interactions (Monitor Closely): - Concurrent use of other local anesthetics: cumulative toxicity risk. - Epinephrine: may prolong anesthetic effect but also increase systemic absorption. - Diuretics (e.g., furosemide): may alter plasma protein binding and affect drug levels.